DLBCL Clinical Trials in Wuhan, Hubei
9 recruitingWuhan, Hubei, China
Showing 1–9 of 9 trials
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled132 locationsNCT05139017
Recruiting
Phase 2
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Liling Zhang40 enrolled1 locationNCT06867536
Recruiting
Early Phase 1
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)B-cell Non Hodgkin Lymphoma (NHL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology24 enrolled1 locationNCT07548697
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Non-Hodgkin LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)
TCRx Therapeutics Co.Ltd18 enrolled1 locationNCT07260812
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Not Applicable
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
LeukaemiaLymphomaMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Zhongnan Hospital196 enrolled1 locationNCT07305337
Recruiting
Phase 1Phase 2
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.97 enrolled21 locationsNCT07124936
Recruiting
Phase 2
Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
DLBCL Germinal Center B-Cell Type
Li Zhiming50 enrolled6 locationsNCT05422066